摘要
目的探讨非小细胞肺癌(NSCLC)组织中金属硫蛋白(metallothionein,MT)的表达及临床意义。方法采用免疫组织化学SP法检测68例NSCLC和25例肺良性疾病中MT的表达,分析其与NSCLC临床病理特征、预后以及耐药蛋白GST-π和TopoⅡ表达的关系。结果 MT在NSCLC组织中表达显著高于肺良性病变组织(P<0.05),与年龄、分化程度有关;MT表达患者术后生存期明显短于不表达者。MT表达和GST-π、TopoⅡ表达无相关性(P>0.05)。结论 MT在NSCLC组织中存在不同程度的高表达,且与某些生物学行为有关,可以作为评价预后的指标。
Objective To investigate the expression and clinical significance of metallothionein（MT） in non-small cell lung cancer, Methods Immunohistochemical methods are used to detect the expressions of MT in 68 cases of non-small cell lung cancer and 25 cases of benign lung disease. The relationships be tween MT expression and clinicopathological factors or patient prognosis and correlations between MT, GST-π, and Topo II were analyzed. Results The expression level of MT was significantly higher in NSCLC than in benign lung disease. There was significant correlation between MT expresssion and age, tumor differentiation. The survival of the patients with high expression of MT as compared to low ex pression of MT was shorter. No significant correlations were observed between MT and GSTn, MT and Topo II , GST-π and Topo II. Conclusion MT was over expressed in various degrees in NSCLC tissues, and related to some biology behaviour and prognosis of NSCLC.
出处
《肿瘤防治研究》
CAS
CSCD
北大核心
2012年第10期1236-1239,共4页
Cancer Research on Prevention and Treatment
关键词
非小细胞肺癌
金属硫蛋白
预后
Non-small cell lung cancer
Metallothionein
Prognosis
